Istradefylline, an adenosine A2a receptor antagonist, ameliorates neutrophilic airway inflammation and psoriasis in mice

Tokano, Mieko Kawano Masaaki Takagi Rie Matsushita Sho

Objective Methods Results Conclusion Extracellular adenosine is produced from secreted adenosine triphosphate by cluster of differentiation (CD)39 and CD73. Both are critical nucleotide metabolizing enzymes of the adenosine generating pathway and are secreted by neuronal or immune cells. Adenosine plays a role in energy processes, neurotransmission and endogenous regulation of inflammatory responses. Istradefylline is a selective adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. We have reported that adenosine primes hypersecretion of interleukin (IL)‐17A through the adenosine A2a receptor. Istradefylline, as well as an inhibitor of CD39 (ARL67156) and an inhibitor of CD73 (AMP‐CP), suppressed IL‐17A production, and the administration of istradefylline to mice with experimental autoimmune encephalomyelitis led to the marked amelioration of the disease. These previous results suggest that adenosine is an endogenous modulator of neutrophilic inflammation. We investigated the effect of istradefylline, ARL67156 and AMP‐CP on other mouse models of neutrophilic inflammation.We tested the effect of istradefylline, ARL67156 and AMP‐CP on ovalbumin‐induced neutrophilic airway inflammation or imiquimod‐induced psoriasis in mice. The two mice models received these drugs orally or percutaneously, respectively. The production of IL‐17A in the lung and ear thickness were used as an index of the effects.We show that istradefylline, ARL67156 and AMP‐CP suppressed the ovalbumin‐induced IL‐17A production in the lung and imiquimod‐induced psoriasis.These results show that adenosine‐mediated IL‐17A production plays a role in neutrophilic inflammation models, and furthermore, istradefylline, ARL67156 and AMP‐CP are effective in animal models of neutrophilic inflammation. Some clinical relevancies in coronavirus disease 2019 are discussed. [ABSTRACT FROM AUTHOR] Copyright of Clinical & Experimental Neuroimmunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)